{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05891769",
            "orgStudyIdInfo": {
                "id": "68169"
            },
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT",
            "officialTitle": "Evaluation of Patients With Suspected Parathyroid Adenoma and Negative or Equivocal 99mTc Sestamibi SPECT/CT Using 18F Fluorocholine PET/CT",
            "acronym": "18FCH",
            "therapeuticArea": [
                "Other"
            ],
            "study": "sestamibi-spect-ct-vs-fluorocholine-pet-ct"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-07-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-26",
            "studyFirstSubmitQcDate": "2023-05-26",
            "studyFirstPostDateStruct": {
                "date": "2023-06-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Andrei Iagaru",
                "investigatorTitle": "Professor of Radiology (Nuclear Medicine)",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Andrei Iagaru",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT"
        },
        "conditionsModule": {
            "conditions": [
                "Parathyroid Adenoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "This is a prospective, single-center, single-arm study enrolling 100 adult participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "18FCH PET/CT",
                    "type": "EXPERIMENTAL",
                    "description": "Participant receive 18F Fluorocholine injection and approximately 45-60 minutes later receive a low dose CT scan from skull base to mid thighs, followed by a static PET emission scan over the same area.",
                    "interventionNames": [
                        "Drug: 18Fluorocholine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "18Fluorocholine",
                    "description": "18F Fluorocholine 5 mCi \u00b1 20% administered intravenously.",
                    "armGroupLabels": [
                        "18FCH PET/CT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of lesions detected by PET/CT for detecting parathyroid adenomas.",
                    "description": "Inclusion criteria suggest recruiting patients with negative or equivocal SPECT/CT, so based on this there will be 0 lesions on SPECT/CT. The goal is to compare/count the number of lesions from PET/CT, if any present versus no lesions with SPECT/CT",
                    "timeFrame": "up to 1 hour"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Suspected parathyroid adenoma (elevated serum calcium and inappropriately normal or high levels of parathyroid hormone)\n2. Negative or equivocal 99mTc Sestamibi SPECT/CT\n3. Able to provide written consent\n4. Total bilirubin \u2264 1.5 x upper limit of normal (ULN)\n5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \u2264 5 xULN\n6. Karnofsky performance status of \\>50 (or ECOG/WHO equivalent)\n7. Women must not be pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women.\n\nExclusion Criteria:\n\n1. Less than 18 years old at the time of radiotracer administration\n2. Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \\< 60 mL/min or serum creatinine \\>1.5 x ULN\n3. QTcF \\>470 msec on electrocardiogram (ECG) or congenital long QT syndrome",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Andrea Otte, DPT",
                    "role": "CONTACT",
                    "phone": "650-736-4183",
                    "email": "anotte@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Andrei Iagaru, MD",
                    "affiliation": "Stanford University",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford Hospital and Clinics",
                    "status": "RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Meredith Durbahn",
                            "role": "CONTACT",
                            "email": "mdurbahn@stanford.edu"
                        },
                        {
                            "name": "Andrei Iagaru, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "22310246",
                    "type": "BACKGROUND",
                    "citation": "Ciappuccini R, Morera J, Pascal P, Rame JP, Heutte N, Aide N, Babin E, Reznik Y, Bardet S. Dual-phase 99mTc sestamibi scintigraphy with neck and thorax SPECT/CT in primary hyperparathyroidism: a single-institution experience. Clin Nucl Med. 2012 Mar;37(3):223-8. doi: 10.1097/RLU.0b013e31823362e5."
                },
                {
                    "pmid": "28121522",
                    "type": "BACKGROUND",
                    "citation": "Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh QY, Vriens MR, de Keizer B, Hope TA, Glastonbury CM, Pampaloni MH, Suh I. 18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. Radiology. 2017 Aug;284(2):460-467. doi: 10.1148/radiol.2016160768. Epub 2017 Jan 25."
                },
                {
                    "pmid": "33674400",
                    "type": "BACKGROUND",
                    "citation": "Hope TA, Graves CE, Calais J, Ehman EC, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell JE, Shen WT, Roman SA, Sosa JA, Kluijfhout WP, Seib CD, Villaneuva-Meyer JE, Pampaloni MH, Suh I. Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. J Nucl Med. 2021 Nov;62(11):1511-1516. doi: 10.2967/jnumed.120.256735. Epub 2021 Mar 5."
                },
                {
                    "pmid": "34301418",
                    "type": "BACKGROUND",
                    "citation": "Graves CE, Hope TA, Kim J, Pampaloni MH, Kluijfhout W, Seib CD, Gosnell JE, Shen WT, Roman SA, Sosa JA, Duh QY, Suh I. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. Surgery. 2022 Jan;171(1):47-54. doi: 10.1016/j.surg.2021.05.056. Epub 2021 Jul 21."
                },
                {
                    "pmid": "11801711",
                    "type": "BACKGROUND",
                    "citation": "DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002 Jan;43(1):92-6. Erratum In: J Nucl Med 2002 Apr;43(4):509."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000236",
                    "term": "Adenoma"
                },
                {
                    "id": "D000010282",
                    "term": "Parathyroid Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000010279",
                    "term": "Parathyroid Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3591",
                    "name": "Adenoma",
                    "asFound": "Adenoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13195",
                    "name": "Parathyroid Neoplasms",
                    "asFound": "Parathyroid Adenoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13192",
                    "name": "Parathyroid Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M13194",
                    "name": "Parathyroid Hormone",
                    "relevance": "LOW"
                },
                {
                    "id": "M19552",
                    "name": "Technetium Tc 99m Sestamibi",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}